Cell and Gene Therapy is a rapidly evolving field that has the potential to revolutionize the treatment of a wide range of diseases. It involves the use of living cells or genes to treat or cure various medical conditions, including cancer, genetic disorders, and autoimmune diseases. In this article, we will explore the development of Cell and Gene Therapy and how it has progressed over the years.
What is Cell Therapy?
Cell therapy is a type of treatment that involves the use of living cells to repair or replace damaged tissue in the body. The concept of cell therapy dates back to the 1950s, when bone marrow transplantation was first performed to treat leukemia. Since then, the field has advanced significantly, and new techniques have been developed to isolate and culture various types of cells for use in therapy.
One recent breakthrough in cell therapy is the use of chimeric antigen receptor (CAR) T-cell therapy to treat certain types of cancer. CAR T-cell therapy involves extracting a patient’s T-cells and genetically modifying them to recognize and attack cancer cells before reinfusing them back into the patient’s body. This approach has shown promising results in clinical trials and has been approved by the FDA for the treatment of certain types of blood cancers (1).
What is Gene Therapy?
Gene therapy, on the other hand, involves the use of genetic material, such as DNA or RNA, to treat or prevent disease. The idea of gene therapy dates back to the 1960s, but it was not until the 1990s that the first successful clinical trial was conducted, which involved treating a patient with severe combined immunodeficiency (SCID) using gene therapy (2).
Since then, the field has advanced significantly, and several gene therapy products have been approved by regulatory agencies around the world. One notable example is Luxturna, a gene therapy product approved by the FDA for the treatment of a rare form of inherited blindness caused by mutations in the RPE65 gene (3).
How has Cell and Gene Therapy developed?
The development of Cell and Gene Therapy has been driven by advances in technology and scientific understanding of how cells and genes work. For example, the use of viral vectors to deliver genetic material into cells has greatly improved the efficiency of gene therapy. In addition, advances in genome editing technology, such as CRISPR-Cas9, have made it possible to precisely edit genes in cells, which could lead to new treatments for genetic diseases (4).
These technological advancements have also enabled the development of novel cell therapies, such as induced pluripotent stem cells (iPSCs), which can be generated from a patient’s own cells and then differentiated into different cell types for use in therapy (5).
What challenges are posed by Cell and Gene Therapy?
Despite the progress made in Cell and Gene Therapy, there are still several challenges that need to be overcome. One of the major challenges is the high cost of these therapies, which can limit access to patients who need them. In addition, there are concerns about the long-term safety and efficacy of these therapies, particularly for gene therapy products, which can have off-target effects on the genome (6). To address these challenges, researchers and regulatory agencies are working to develop guidelines and standards for the development and evaluation of Cell and Gene Therapy products.
In conclusion, the development of Cell and Gene Therapy has come a long way since its inception in the 1950s and 1960s. Advances in technology and scientific understanding have led to the development of novel therapies, such as CAR T-cell therapy and gene editing, which have shown promising results in clinical trials. While there are still challenges to overcome, the potential benefits of these therapies are vast and they have the potential to revolutionize the treatment of a wide range of diseases.
Mantell Associates is a specialist Pharmaceutical and Life Sciences headhunting firm. To find out how we can assist with your business requirements, get in touch with Robin Mantell at +1 (786) 485 1298 or robin.mantell@mantellassociates.com.
Sources:
-
Maude, S. L., et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371(16), 1507-1517. doi: 10.1056/NEJMoa1407222
-
Bordignon, C., et al. (1995). Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science, 270(5235), 470-475. doi: 10.1126/science. 270.5235.470
-
FDA. (2017). FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss
-
Jinek, M., et al. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816-821. doi: 10.1126/science.1225829
-
Takahashi, K., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861-872. doi: 10.1016/j.cell.2007.11.019
-
VandenDriessche, T., & Chuah, M. K. (2015). Gene therapy: From bench to bedside. In Encyclopedia of Life Sciences (ELS). doi: 10.1002/9780470015902.a0024371